Okumuş N et al., 2021-05-04: Prospective randomized single-blind phase 3 trial in 66 severe COVID-19 patients in Turkey: adding five days of enteral ivermectin gave higher clinical improvement (73.3% vs 53.3%) and lower mortality (20% vs 30%), neither statistically significant.
the rate of clinical improvement was 73.3% (22/30) in the study group and was 53.3% (16/30) in the control group (p = 0.10)
Okumuş N et al., 2021-05-04: Prospective randomized single-blind phase 3 trial in 66 severe COVID-19 patients in Turkey: adding five days of enteral ivermectin gave higher clinical improvement (73.3% vs 53.3%) and lower mortality (20% vs 30%), neither statistically significant. Prospective, randomized, controlled, single-blind phase 3 study, N=66 analysed after excluding 6 with MDR1/ABCB1 mutations affecting ivermectin metabolism (36 randomized to ivermectin, 30 controls); Turkey. Ivermectin 200 micrograms/kg/day for 5 days as an enteral solution added to a reference protocol of hydroxychloroquine + favipiravir + azithromycin; controls received the same without ivermectin. Clinical improvement 73.3% vs 53.3% (p=0.10); mortality 6 (20%) vs 9 (30%) (p=0.37); improvements in CRP, D-dimer and other laboratory parameters were more pronounced in the ivermectin group. Authors declare neither financial nor non-financial competing interests. Bearing PARTLY SUPPORTS because the direction favoured ivermectin at every clinical endpoint but none reached significance in this small trial. Study type: randomized trial.
